REGN2176-3
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for REGN2176-3, covering 2015-02-11 to 2020-10-26. Get the full timeline:
Most recent: Clinical Trial Update: Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) [Phase 2]